• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by ENDRA Life Sciences Inc.

    2/14/25 5:04:12 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NDRA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    ENDRA Life Sciences Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    29273B302

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29273B302


    1Names of Reporting Persons

    L1 Capital Global Opportunities Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    35,589.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    35,589.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    35,589.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.22 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ENDRA Life Sciences Inc.
    (b)Address of issuer's principal executive offices:

    3600 Green Court, Suite 350, Ann Arbor, MI 48105
    Item 2. 
    (a)Name of person filing:

    L1 Capital Global Opportunities Master Fund, Ltd.
    (b)Address or principal business office or, if none, residence:

    161A Shedden Road, 1 Artillery Court, PO Box 10085 Grand Cayman, Cayman Islands KY1-1001
    (c)Citizenship:

    Cayman Islands
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    29273B302
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    35,589 This amendment refers to a Schedule 13G filed with the Securities and Exchange Commission on June 14, 2024, covering 7,921,648 shares of Common Stock purchased and underlying Warrants purchased on June 4, 2024. The amounts in Row (5), (7) and (9) consists of Common Stock underlying 35,589 Warrants, which are subject to a 9.99% beneficial ownership limitation. The percentage set forth on Row (11) of the cover page for the reporting person is based on 536,908 shares of Common Stock outstanding as of November 19, 2024 based on the Issuer's Amendment No. 1 to the Quarterly Report on Form 10-Q/A filed with the Securities and Exchange Commission on November 21, 2024. David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer's securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.
    (b)Percent of class:

    6.22  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    35,589

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    35,589

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    L1 Capital Global Opportunities Master Fund, Ltd.
     
    Signature:/s/ David Feldman
    Name/Title:David Feldman, Director
    Date:02/14/2025
    Get the next $NDRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NDRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NDRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease. With a sharpened mission to transform the way steatotic liver disease (SLD) is diagnosed and managed, ENDRA is developing a revolutionary, low-cost, point-of-care diagnostic device—essentially a "blood pressure cuff" for the liver. This strategic shift is aimed squarel

      5/15/25 4:05:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

      Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies. ENDRA's management has thoroughly evaluated the Company's technical capabilities and go-to-market strategy for TAEUS Liver and dete

      3/31/25 8:05:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

      3/31/25 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Leadership Updates

    Live Leadership Updates

    See more
    • ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

      ANN ARBOR, MI / ACCESSWIRE / June 15, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms. Pestrikova will assume all day-to-day responsibilities previously performed by ENDRA's Chief Financial Officer David Wells, who will leave the Company effective June 18, 2021 to pursue another opportunity.Ms. Pestrikova has supported ENDRA since 2014 and has been actively involved in ENDRA's financial planning and analysis, accounting and SEC reporting functions. Previously, Ms. Pestrikova was a financial analyst at a

      6/15/21 8:35:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

      4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 3:28:10 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

      4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      8/29/24 4:30:01 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NDRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $NDRA
    SEC Filings

    See more
    • Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

      4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 3:28:10 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: New insider Ubs Group Ag claimed ownership of 146,012 shares (SEC Form 3)

      3/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 2:47:08 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

      4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      8/29/24 4:30:01 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      6/14/24 4:01:26 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      6/14/24 8:00:02 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      3/10/23 12:18:14 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/30/25 8:00:47 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by ENDRA Life Sciences Inc.

      10-Q - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/15/25 4:59:32 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/15/25 4:58:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Financials

    Live finance-specific insights

    See more
    • ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

      3/31/25 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC ("Nasdaq"). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listing. "Now that we have regained compliance with Nasdaq's listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22nd conference call,

      11/22/24 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

      ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call. Participants are encouraged to pre-register

      8/13/24 4:05:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care